ScoreWhy is Beryl Drugs Ltd ?
1
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 8.19%
- Poor long term growth as Net Sales has grown by an annual rate of 6.33% and Operating profit at 5.39% over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 0.92
2
Flat results in Jun 26
3
With ROCE of 7.6, it has a Very Attractive valuation with a 1.1 Enterprise value to Capital Employed
- The stock is trading at a discount compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of -11.93%, its profits have risen by 39% ; the PEG ratio of the company is 0.1
4
Majority shareholders : Non Institution
5
Underperformed the market in the last 1 year
- Even though the market (BSE500) has generated returns of 3.48% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -11.93% returns
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Beryl Drugs should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Beryl Drugs for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Beryl Drugs
-3.89%
-0.19
64.41%
Sensex
-3.75%
-0.28
13.41%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
6.33%
EBIT Growth (5y)
5.39%
EBIT to Interest (avg)
0.92
Debt to EBITDA (avg)
2.51
Net Debt to Equity (avg)
0.22
Sales to Capital Employed (avg)
1.58
Tax Ratio
20.25%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
6.35%
ROE (avg)
5.66%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
19
Industry P/E
37
Price to Book Value
1.18
EV to EBIT
12.55
EV to EBITDA
5.46
EV to Capital Employed
1.15
EV to Sales
0.63
PEG Ratio
0.11
Dividend Yield
NA
ROCE (Latest)
7.63%
ROE (Latest)
6.28%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
No Trend
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend5What is working for the Company
NET SALES(Latest six months)
At Rs 13.04 cr has Grown at 29.75%
PAT(Latest six months)
Higher at Rs 0.78 cr
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...
Here's what is working for Beryl Drugs
Net Sales - Latest six months
At Rs 13.04 cr has Grown at 29.75%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Profit After Tax (PAT) - Latest six months
Higher at Rs 0.78 cr
than preceding 12 month period ended Jun 2026 of Rs 0.01 crMOJO Watch
In the half year the company has already crossed PAT of the previous twelve months
PAT (Rs Cr)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
